What is Transgene?
Transgene is a biotechnology firm dedicated to the design and development of novel immunotherapies aimed at treating cancer. The company's robust product portfolio features personalized therapeutic vaccines, such as TG4050, oncolytic viruses derived from its proprietary Invir.IO platform, and other advanced genetic engineering technologies like myvac. By integrating cutting-edge genetic engineering with artificial intelligence, Transgene seeks to significantly enhance the efficacy of cancer treatments. The company's strategic focus is on personalized medicine, targeting a broad spectrum of cancer patients with the ultimate goal of improving patient outcomes and survival rates.
How much funding has Transgene raised?
Transgene has raised a total of $144M across 2 funding rounds:
Debt
$22.4M
Stock/Share Issuance
$121.6M
Debt (2016): $22.4M with participation from European Investment Bank
Stock/Share Issuance (2025): $121.6M led by Dassault Group
Key Investors in Transgene
European Investment Bank
The European Investment Bank, established in 1958 and headquartered in Luxembourg, is the European Union's nonprofit long-term lending and finance institution, providing crucial financial backing for significant projects.
Dassault Group
Dassault Group is a French industrial conglomerate founded in 1929, specializing in aerospace manufacturing and technology solutions, including aircraft production and software development.
What's next for Transgene?
With the recent influx of major strategic investment, Transgene is poised for accelerated growth and innovation in the competitive oncology landscape. The company's focus on personalized immunotherapies, leveraging advanced AI and genetic engineering, positions it at the forefront of next-generation cancer treatments. Future developments are likely to concentrate on clinical trial progression for its lead candidates, expansion of its technology platforms, and strategic partnerships to broaden market access. The enterprise-level funding suggests a mature stage of development, enabling Transgene to scale its operations and R&D efforts to meet the growing demand for effective, tailored cancer therapies.
See full Transgene company page
